Company Overview and News

102
OTIC / Otonomy, Inc. FORM 8-K (Current Report)

13h sec.gov
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
OTIC

104
OTIC / Otonomy, Inc. 10-Q (Quarterly Report)

2018-05-09 sec.gov
otic-10q_20180331.htm UNITED STATES S
OTIC

101
OTIC / Otonomy, Inc. 8-K (Current Report)

2018-05-09 sec.gov
otic-8k_20180509.htm
OTIC

98
Otonomy to Report First Quarter 2018 Financial Results and Provide Corporate Update

2018-05-02 globenewswire
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial results for the first quarter 2018 as well as provide a corporate update at 4:30 p.m. EDT on May 9, 2018.
OTIC

117
OTIC / Otonomy, Inc. DEF 14A

2018-04-27 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2
OTIC

112
Otonomy (OTIC) Sees Hammer Chart Pattern: Time to Buy?

2018-04-09 zacks
Otonomy, Inc. (OTIC - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because OTIC recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
SNSS OTIC

OTIC : Otonomy Stock Analysis and Research Report

2017-11-08 - Asif

Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIOâ (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement (TTP) surgery in pediatric patients, has achieved positive pivotal trial results in patients with acute otitis externa (AOE), and has completed a successful Phase 2 trial in patients with acute otitis media with tubes (AOMT). OTO-104 is a steroid in development for the treatment of Ménière’s disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière’s disease patients are underway with results expected during the second half of 2017, and a Phase 2 trial has been initiated in patients at risk for cisplatin-induced hearing loss. OTO-311 is a N-Methyl-D-Aspartate (NMDA) receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial with a Phase 2 trial expect...

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to OTIC / Otonomy, Inc. on message board site Silicon Investor.

Rare Earth Elements and Exotic Metals Robotics and Artificial Intelligence
ARAY Accuray Cyberknife Robotic RadioSurgery Braintech Inc. BRHI Robotics
God Bless America - The Patriotic Thread Transkaryotic(tktx)
Synbiotics Corp. Wells Notice
ROBV-Robotic Vision Systems--DANG!! TNSB - Transbotics Corporation
CUSIP: 68906L105